MX375402B - Nuevo anticuerpo anti-dengue de espectro completo. - Google Patents

Nuevo anticuerpo anti-dengue de espectro completo.

Info

Publication number
MX375402B
MX375402B MX2016009991A MX2016009991A MX375402B MX 375402 B MX375402 B MX 375402B MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 375402 B MX375402 B MX 375402B
Authority
MX
Mexico
Prior art keywords
antibody agents
new full
spectrum anti
dengue antibody
serotypes
Prior art date
Application number
MX2016009991A
Other languages
English (en)
Spanish (es)
Other versions
MX2016009991A (es
Inventor
Kannan Tharakaraman
Ram Sasisekharan
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2016009991A publication Critical patent/MX2016009991A/es
Publication of MX375402B publication Critical patent/MX375402B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016009991A 2014-02-11 2015-02-11 Nuevo anticuerpo anti-dengue de espectro completo. MX375402B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (2)

Publication Number Publication Date
MX2016009991A MX2016009991A (es) 2016-10-07
MX375402B true MX375402B (es) 2025-03-06

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009991A MX375402B (es) 2014-02-11 2015-02-11 Nuevo anticuerpo anti-dengue de espectro completo.

Country Status (12)

Country Link
US (3) US9902764B2 (enExample)
EP (1) EP3104888A4 (enExample)
JP (1) JP6707455B2 (enExample)
KR (1) KR20160119806A (enExample)
CN (1) CN106413749B (enExample)
AU (1) AU2015217149B2 (enExample)
BR (1) BR112016017764A2 (enExample)
CA (1) CA2938495A1 (enExample)
IL (1) IL246788A0 (enExample)
MX (1) MX375402B (enExample)
SG (2) SG10201807826XA (enExample)
WO (1) WO2015123362A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
BR112015002605B1 (pt) 2012-08-07 2023-03-07 Massachusetts Institute Of Technology Agente de anticorpo específico para o vírus da dengue, seu uso, kit, composição farmacêutica e método para sua produção
CN106211773B (zh) 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用
EP3104888A4 (en) 2014-02-11 2017-08-09 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
SG11201706014PA (en) 2015-02-05 2017-08-30 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
CR20190291A (es) 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
KR20200132938A (ko) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
HUE034801T2 (en) 2002-11-01 2018-02-28 Glaxosmithkline Biologicals Sa Drying procedure
WO2005056600A2 (en) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP1924280A4 (en) 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
US8680022B2 (en) 2008-02-05 2014-03-25 Bicycle Therapeutics Limited Methods and compositions
JP2012504602A (ja) 2008-10-05 2012-02-23 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ C型肝炎抗体およびその使用
WO2010043977A2 (en) 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
KR20110097923A (ko) 2008-12-05 2011-08-31 엘파스, 인크. 항-지질 항체 결정 구조를 이용한 항체 설계
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) * 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
WO2013089647A1 (en) 2011-12-16 2013-06-20 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
WO2013173348A1 (en) * 2012-05-14 2013-11-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Cross-reactive antibodies against dengue virus and uses thereof
BR112015002605B1 (pt) 2012-08-07 2023-03-07 Massachusetts Institute Of Technology Agente de anticorpo específico para o vírus da dengue, seu uso, kit, composição farmacêutica e método para sua produção
EP3104888A4 (en) 2014-02-11 2017-08-09 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
CN106211773B (zh) * 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用

Also Published As

Publication number Publication date
SG11201606163QA (en) 2016-08-30
CN106413749B (zh) 2022-04-05
BR112016017764A2 (pt) 2017-10-10
US20180237504A1 (en) 2018-08-23
US10519220B2 (en) 2019-12-31
AU2015217149B2 (en) 2020-09-10
JP6707455B2 (ja) 2020-06-10
US9902764B2 (en) 2018-02-27
SG10201807826XA (en) 2018-10-30
JP2017507131A (ja) 2017-03-16
EP3104888A4 (en) 2017-08-09
WO2015123362A1 (en) 2015-08-20
MX2016009991A (es) 2016-10-07
CA2938495A1 (en) 2015-08-20
KR20160119806A (ko) 2016-10-14
EP3104888A1 (en) 2016-12-21
US11421018B2 (en) 2022-08-23
IL246788A0 (en) 2016-08-31
CN106413749A (zh) 2017-02-15
AU2015217149A1 (en) 2016-09-08
US20200207841A1 (en) 2020-07-02
US20150368321A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
MX2019008736A (es) Anticuerpos anti-virus del dengue y usos de los mismos.
MX375402B (es) Nuevo anticuerpo anti-dengue de espectro completo.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX388181B (es) Anticuerpos anti-pd-1.
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
EA201891992A1 (ru) Химерные рецепторы и способы их применения
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
PH12016501366A1 (en) Novel anti-baff antibodies
MX2019005426A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
PE20170765A1 (es) Moleculas de union tri-especificas y metodos de uso de las mismas
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
NZ759835A (en) Cd38 modulating antibody
EA201590918A1 (ru) Антитела к bmp-6
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن

Legal Events

Date Code Title Description
FG Grant or registration